IFNB1 and Castleman-Kojima disease: The JAK 1/2 inhibitor ruxolitinib is commonly used to treat myelofibrosis.[18] Although the iMCD-TAFRO syndrome pathophysiology has not been identified, type I IFN is involved in its pathogenesis, and IFN-β-induced mTOR activation depends on both JAK and mTORC1 signaling.